Demographic pressures boost longevity biotech market to $46.61 billion by 2033.

The article discusses the surge in healthcare spending for people over 65 in the US, driving investment in longevity solutions. The global longevity biotech market is expected to grow from $27.15 billion in 2024 to $46.61 billion by 2033 at a 6.5% CAGR. The anti-aging drugs market is projected to grow from $79 million to $2.8 billion by 2040 at a 27% growth rate. Companies like Avant Technologies, HCW Biologics, Solid Biosciences, ProMIS Neurosciences, and uniQure N.V. are well-positioned to benefit from these market trends.

Healthcare spending for Americans over 65 has reached unprecedented levels, with annual per-person spending of $22,356 compared to $4,217 for children[1]. This demographic shift, coupled with the global aging population, is fueling significant investment in longevity solutions. The global longevity biotech market, valued at $27.15 billion in 2024, is projected to grow to $46.61 billion by 2033 at a compound annual growth rate (CAGR) of 6.5%[2]. Additionally, the anti-aging drugs market is expected to expand from $79 million to $2.8 billion by 2040, growing at a 27% CAGR[3].

Companies such as Avant Technologies, Inc., HCW Biologics Inc., Solid Biosciences Inc., ProMIS Neurosciences, Inc., and uniQure N.V. are well-positioned to capitalize on these market trends. Avant Technologies, for instance, has pivoted into the longevity biotech sector through a joint venture with Austrianova, forming Klothonova, Inc. This partnership aims to develop cell-based therapies using Klotho-producing cells, targeting conditions like Alzheimer's disease, heart disease, and kidney disease[4].

HCW Biologics has designated HCW11-040, a TRBC-pembrolizumab-based immune checkpoint inhibitor, as its franchise immunotherapeutic for internal clinical development. This multi-functional fusion protein combines pembrolizumab with interleukin IL-7, IL-15, and TGF-β receptor components, demonstrating superior immune-cell activation and tumor infiltration enhancement in preclinical studies[5].

Solid Biosciences, meanwhile, has dosed 15 participants in its Phase 1/2 INSPIRE DUCHENNE trial for SGT-003 gene therapy targeting Duchenne muscular dystrophy, with no serious adverse events observed. The company is also preparing to initiate Phase 1b trials for SGT-212 targeting Friedreich's ataxia and SGT-501 targeting catecholaminergic polymorphic ventricular tachycardia in the fourth quarter of 2025[6].

ProMIS Neurosciences has received DSMB approval to advance to the final dose escalation cohort in its Phase 1b PRECISE-AD trial of PMN310 for Alzheimer's disease treatment. This antibody targets toxic amyloid-beta oligomers, avoiding plaque binding to potentially reduce safety concerns[7].

uniQure N.V. achieved sustained increases in α-Gal A enzyme activity in its Phase I/IIa trial of AMT-191 gene therapy for Fabry disease, with all patients discontinuing enzyme replacement therapy and maintaining stable plasma lyso-Gb3 levels[8].

These advancements underscore the potential of the longevity biotech sector to address the growing healthcare challenges posed by an aging global population. As these companies continue to develop innovative treatments, investors and financial professionals should closely monitor their progress and the broader market trends.